A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional Experience

Benny Johnson(The University of Texas MD Anderson Cancer Center), Axel Grothey(Campbell Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), David M. Nagorney(Mayo Clinic in Arizona), Rory L. Smoot(Pancreas Centre (Canada)), Michael G. Haddock(Mayo Clinic in Arizona), Zhaohui Jin(XinHua Hospital), Eric J. Dozois(Mayo Clinic), James A. Martenson(Mayo Clinic), David W. Larson(Mayo Clinic)
The Oncologist
February 14, 2018
10.1634/theoncologist.2017-0456
Cited by 23

Related Papers

Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
|New England Journal of Medicine|2018|1.1k
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
|The Lancet Oncology|2015|954
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
|Journal of Clinical Oncology|2008|695